Equity Overview
Price & Market Data
Price: $0.814
Daily Change: -$0.0583 / 7.16%
Range: $0.77 - $0.90
Market Cap: $71,985,560
Volume: 1,431,178
Performance Metrics
1 Week: 5.31%
1 Month: -12.16%
3 Months: -48.74%
6 Months: -60.91%
1 Year: -80.55%
YTD: -51.32%
Company Details
Employees: 147
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.